Internal Medicine, Hematology & Oncology · Iowa City, IA
NPI
1003103383
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
200 Hawkins Dr, Dept of Internal Medicine
Iowa City, IA, 52242
Phone (319) 356-1616
Groups this clinician bills Medicare through
Medicare paid, 2024
$41K
525 services
Medicare patients, 2024
202
Average age 73
Drug cost, 2024
$7.9M
984 prescriptions
Company payments, 2025
$0
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Grerk Sutamtewagul was code 99214 (office e&m - established), 259 times for 119 patients. In total Grerk Sutamtewagul billed 525 services in 15 codes, and Medicare paid $41K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-01-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 259 | 119 | $61.28 | $16K |
| 99215 Office E&M - Established | Facility | 83 | 53 | $102.13 | $8,477 |
| 99233 Hospital E&M - Subsequent | Facility | 76 | 25 | $86.84 | $6,600 |
| 99205 Office E&M - New | Facility | 26 | 26 | $127.06 | $3,304 |
| 99223 Hospital E&M - Initial | Facility | 23 | 22 | $122.53 | $2,818 |
| 99232 Hospital E&M - Subsequent | Facility | 14 | 11 | $57.80 | $809 |
| 99239 Hospital Discharge Management | Facility | 14 | 13 | $83.81 | $1,173 |
By year: 2022 $50K for 711 services; 2023 $59K for 779 services; 2024 $41K for 525 services.
Medicare prescription drug claims, 2024
In 2024, the drug Grerk Sutamtewagul prescribed most often to Medicare patients was Calquence (Acalabrutinib Maleate), with 108 prescriptions and refills. In total Grerk Sutamtewagul wrote 984 Medicare prescriptions that cost $7.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calquence Acalabrutinib Maleate | 108 | 108 | 14 | $1.7M |
| Jakafi Ruxolitinib Phosphate | 96 | 96 | 13 | $1.5M |
| Imatinib Mesylate Generic | 75 | 75 | 12 | $9,179 |
| Acyclovir Generic | 44 | 57 | 11 | $514 |
| Brukinsa Zanubrutinib | 38 | 38 | Under 11 | $316K |
| Ondansetron Hcl Generic | 36 | 36 | 19 | $496 |
| Imbruvica Ibrutinib | 36 | 41 | Under 11 | $582K |
| Venclexta Venetoclax | 32 | 32 | 13 | $214K |
| Eliquis Apixaban | 29 | 31 | Under 11 | $18K |
| Xarelto Rivaroxaban | 29 | 42 | Under 11 | $23K |
| Sprycel Dasatinib | 28 | 32 | Under 11 | $406K |
| Ojjaara Momelotinib Dihydrochloride | 28 | 28 | Under 11 | $750K |
| Tasigna Nilotinib Hcl | 26 | 26 | Under 11 | $501K |
| Jaypirca Pirtobrutinib | 26 | 26 | Under 11 | $487K |
| Hydroxyurea Generic | 26 | 34 | Under 11 | $258 |
Brand drugs: 576 claims; generic drugs: 408 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Grerk Sutamtewagul $0 (- in general payments such as food, travel and fees) from 3 companies.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.